Guggenheim reiterates Absci stock rating on endometriosis trial delay
Covered in this story
Tracked from this story
Guggenheim’s $15 target on $ABSI is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
Guggenheim’s track record →Call it yourself
No member calls on $ABSI yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Absci Corp →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.